Shopping Cart
- Remove All
- Your shopping cart is currently empty
Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a monoclonal antibody targeting phosphatidylserine (PS) with vascular targeting and immunomodulatory properties, capable of reactivating anti-tumor immunity to inhibit tumor growth. It has anti-cancer activity and is frequently used with Paclitaxel and Carboplatin in non-small cell lung cancer studies.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $497 | In Stock | |
5 mg | $1,230 | In Stock | |
10 mg | $1,990 | In Stock | |
25 mg | $2,960 | In Stock | |
50 mg | $3,920 | In Stock | |
100 mg | $5,380 | In Stock |
Description | Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a monoclonal antibody targeting phosphatidylserine (PS) with vascular targeting and immunomodulatory properties, capable of reactivating anti-tumor immunity to inhibit tumor growth. It has anti-cancer activity and is frequently used with Paclitaxel and Carboplatin in non-small cell lung cancer studies. |
In vitro | Bavituximab binds to exposed phosphatidylserine (PS) molecules through the serum protein β2-glycoprotein 1 (β2GP1)[1], inducing antibody-dependent cellular cytotoxicity and leading to the destruction of tumor vessels[1]. Bavituximab (10 μg/mL; 48 h) binds to PS induced by 10 μM Sorafenib in HUVEC and bEnd.3 cells[2]. |
In vivo | Sorafenib induces anionic phospholipid exposure in a mouse tumor model, which is detected by Bavituximab (100 μg/mouse; i.v.; single dose) administered 48 hours post-Sorafenib treatment[2]. |
Alias | Anti-PS MAb 3G4 |
Molecular Weight | 145.3 kDa |
Cas No. | 648904-28-3 |
Storage | store at low temperature | store at -80°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.